Salvage chemotherapy for patients with advanced pure seminoma

Jacqueline Vuky, S. K. Tickoo, J. Sheinfeld, J. Bacik, A. Amsterdam, M. Mazumdar, V. Reuter, D. F. Bajorin, G. J. Bosl, R. J. Motzer

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: We describe the response to conventional or high-dose salvage chemotherapy in patients with advanced seminoma who experience disease progression after receiving first-line platinum-based treatment. Patients and Methods: Twenty-seven patients with progressive, advanced, pure seminoma were treated with salvage chemotherapy. Fifteen patients were treated with conventional-dose cisplatin-and-ifosfamide combination chemotherapy. Twelve patients were treated with high-dose chemotherapy followed by autologous stem-cell rescue. Results: Fifteen patients (56%) achieved a complete response (CR), nine achieved CR with a conventional-dose cisplatin and ifosfamide program, and six experienced CR after high-dose chemotherapy. Fourteen patients (52%) are alive and disease-free, with 13 (48%) continuously disease-free at a median follow-up of 72 months. Twelve (57%) of 21 patients whose pretreatment tumors were studied morphologically were found to have seminoma with atypia. Eight patients underwent resection after salvage chemotherapy; six with histologic findings of necrotic debris/fibrosis alone are alive and disease-free at last follow-up. Both patients with viable seminoma found at surgery died of disease. Conclusion: Most patients with advanced seminoma are cured with standard first-line programs of cisplatin and etoposide with or without bleomycin. A small minority of patients with pure seminoma have resistant tumors and require salvage chemotherapy. In this setting, approximately 50% of patients with recurrent pure seminoma achieve durable CR with conventional or high-dose salvage chemotherapy. Identification of biologic markers to predict clinical outcome and an enhanced understanding of the basic biologic features of seminoma may lead to improvements in the management of this disease.

Original languageEnglish (US)
Pages (from-to)297-301
Number of pages5
JournalJournal of Clinical Oncology
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Seminoma
Drug Therapy
Cisplatin
Ifosfamide
Bleomycin
Etoposide
Disease Management
Combination Drug Therapy
Platinum
Disease Progression
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vuky, J., Tickoo, S. K., Sheinfeld, J., Bacik, J., Amsterdam, A., Mazumdar, M., ... Motzer, R. J. (2002). Salvage chemotherapy for patients with advanced pure seminoma. Journal of Clinical Oncology, 20(1), 297-301. https://doi.org/10.1200/JCO.20.1.297

Salvage chemotherapy for patients with advanced pure seminoma. / Vuky, Jacqueline; Tickoo, S. K.; Sheinfeld, J.; Bacik, J.; Amsterdam, A.; Mazumdar, M.; Reuter, V.; Bajorin, D. F.; Bosl, G. J.; Motzer, R. J.

In: Journal of Clinical Oncology, Vol. 20, No. 1, 01.01.2002, p. 297-301.

Research output: Contribution to journalArticle

Vuky, J, Tickoo, SK, Sheinfeld, J, Bacik, J, Amsterdam, A, Mazumdar, M, Reuter, V, Bajorin, DF, Bosl, GJ & Motzer, RJ 2002, 'Salvage chemotherapy for patients with advanced pure seminoma', Journal of Clinical Oncology, vol. 20, no. 1, pp. 297-301. https://doi.org/10.1200/JCO.20.1.297
Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M et al. Salvage chemotherapy for patients with advanced pure seminoma. Journal of Clinical Oncology. 2002 Jan 1;20(1):297-301. https://doi.org/10.1200/JCO.20.1.297
Vuky, Jacqueline ; Tickoo, S. K. ; Sheinfeld, J. ; Bacik, J. ; Amsterdam, A. ; Mazumdar, M. ; Reuter, V. ; Bajorin, D. F. ; Bosl, G. J. ; Motzer, R. J. / Salvage chemotherapy for patients with advanced pure seminoma. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 1. pp. 297-301.
@article{d933c9f4d2b24de08bfa6473008d09c6,
title = "Salvage chemotherapy for patients with advanced pure seminoma",
abstract = "Purpose: We describe the response to conventional or high-dose salvage chemotherapy in patients with advanced seminoma who experience disease progression after receiving first-line platinum-based treatment. Patients and Methods: Twenty-seven patients with progressive, advanced, pure seminoma were treated with salvage chemotherapy. Fifteen patients were treated with conventional-dose cisplatin-and-ifosfamide combination chemotherapy. Twelve patients were treated with high-dose chemotherapy followed by autologous stem-cell rescue. Results: Fifteen patients (56{\%}) achieved a complete response (CR), nine achieved CR with a conventional-dose cisplatin and ifosfamide program, and six experienced CR after high-dose chemotherapy. Fourteen patients (52{\%}) are alive and disease-free, with 13 (48{\%}) continuously disease-free at a median follow-up of 72 months. Twelve (57{\%}) of 21 patients whose pretreatment tumors were studied morphologically were found to have seminoma with atypia. Eight patients underwent resection after salvage chemotherapy; six with histologic findings of necrotic debris/fibrosis alone are alive and disease-free at last follow-up. Both patients with viable seminoma found at surgery died of disease. Conclusion: Most patients with advanced seminoma are cured with standard first-line programs of cisplatin and etoposide with or without bleomycin. A small minority of patients with pure seminoma have resistant tumors and require salvage chemotherapy. In this setting, approximately 50{\%} of patients with recurrent pure seminoma achieve durable CR with conventional or high-dose salvage chemotherapy. Identification of biologic markers to predict clinical outcome and an enhanced understanding of the basic biologic features of seminoma may lead to improvements in the management of this disease.",
author = "Jacqueline Vuky and Tickoo, {S. K.} and J. Sheinfeld and J. Bacik and A. Amsterdam and M. Mazumdar and V. Reuter and Bajorin, {D. F.} and Bosl, {G. J.} and Motzer, {R. J.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1200/JCO.20.1.297",
language = "English (US)",
volume = "20",
pages = "297--301",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Salvage chemotherapy for patients with advanced pure seminoma

AU - Vuky, Jacqueline

AU - Tickoo, S. K.

AU - Sheinfeld, J.

AU - Bacik, J.

AU - Amsterdam, A.

AU - Mazumdar, M.

AU - Reuter, V.

AU - Bajorin, D. F.

AU - Bosl, G. J.

AU - Motzer, R. J.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Purpose: We describe the response to conventional or high-dose salvage chemotherapy in patients with advanced seminoma who experience disease progression after receiving first-line platinum-based treatment. Patients and Methods: Twenty-seven patients with progressive, advanced, pure seminoma were treated with salvage chemotherapy. Fifteen patients were treated with conventional-dose cisplatin-and-ifosfamide combination chemotherapy. Twelve patients were treated with high-dose chemotherapy followed by autologous stem-cell rescue. Results: Fifteen patients (56%) achieved a complete response (CR), nine achieved CR with a conventional-dose cisplatin and ifosfamide program, and six experienced CR after high-dose chemotherapy. Fourteen patients (52%) are alive and disease-free, with 13 (48%) continuously disease-free at a median follow-up of 72 months. Twelve (57%) of 21 patients whose pretreatment tumors were studied morphologically were found to have seminoma with atypia. Eight patients underwent resection after salvage chemotherapy; six with histologic findings of necrotic debris/fibrosis alone are alive and disease-free at last follow-up. Both patients with viable seminoma found at surgery died of disease. Conclusion: Most patients with advanced seminoma are cured with standard first-line programs of cisplatin and etoposide with or without bleomycin. A small minority of patients with pure seminoma have resistant tumors and require salvage chemotherapy. In this setting, approximately 50% of patients with recurrent pure seminoma achieve durable CR with conventional or high-dose salvage chemotherapy. Identification of biologic markers to predict clinical outcome and an enhanced understanding of the basic biologic features of seminoma may lead to improvements in the management of this disease.

AB - Purpose: We describe the response to conventional or high-dose salvage chemotherapy in patients with advanced seminoma who experience disease progression after receiving first-line platinum-based treatment. Patients and Methods: Twenty-seven patients with progressive, advanced, pure seminoma were treated with salvage chemotherapy. Fifteen patients were treated with conventional-dose cisplatin-and-ifosfamide combination chemotherapy. Twelve patients were treated with high-dose chemotherapy followed by autologous stem-cell rescue. Results: Fifteen patients (56%) achieved a complete response (CR), nine achieved CR with a conventional-dose cisplatin and ifosfamide program, and six experienced CR after high-dose chemotherapy. Fourteen patients (52%) are alive and disease-free, with 13 (48%) continuously disease-free at a median follow-up of 72 months. Twelve (57%) of 21 patients whose pretreatment tumors were studied morphologically were found to have seminoma with atypia. Eight patients underwent resection after salvage chemotherapy; six with histologic findings of necrotic debris/fibrosis alone are alive and disease-free at last follow-up. Both patients with viable seminoma found at surgery died of disease. Conclusion: Most patients with advanced seminoma are cured with standard first-line programs of cisplatin and etoposide with or without bleomycin. A small minority of patients with pure seminoma have resistant tumors and require salvage chemotherapy. In this setting, approximately 50% of patients with recurrent pure seminoma achieve durable CR with conventional or high-dose salvage chemotherapy. Identification of biologic markers to predict clinical outcome and an enhanced understanding of the basic biologic features of seminoma may lead to improvements in the management of this disease.

UR - http://www.scopus.com/inward/record.url?scp=0036137584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036137584&partnerID=8YFLogxK

U2 - 10.1200/JCO.20.1.297

DO - 10.1200/JCO.20.1.297

M3 - Article

VL - 20

SP - 297

EP - 301

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -